Top Page
Dr. Martens Plc
(LSE:DOCS)
Dr. Martens Plc (DOCS) vs. iShares MSCI United Kingdom ETF (EWC)
Dr. Martens Plc Business Overview & Revenue Model
Dr. Martens Plc Earnings Call Summary
Dr. Martens Plc Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 805.90M | 877.10M | 787.60M | 1.00B | 908.30M | 773.00M |
| Gross Profit | 528.00M | 575.20M | 511.70M | 618.10M | 578.80M | 470.50M |
| EBITDA | 84.40M | 196.30M | 110.50M | 235.00M | 265.10M | 143.30M |
| Net Income | 29.40M | 69.20M | 4.50M | 128.90M | 181.20M | 34.70M |
Balance Sheet | ||||||
| Total Assets | 932.40M | 952.40M | 889.80M | 992.60M | 859.10M | 652.80M |
| Cash, Cash Equivalents and Short-Term Investments | 94.90M | 111.10M | 155.90M | 157.50M | 228.00M | 113.60M |
| Total Debt | 449.70M | 468.60M | 404.10M | 451.80M | 393.80M | 366.40M |
| Total Liabilities | 597.90M | 584.20M | 523.40M | 588.40M | 530.90M | 502.10M |
| Stockholders Equity | 334.50M | 368.20M | 366.40M | 404.20M | 328.20M | 150.70M |
Cash Flow | ||||||
| Free Cash Flow | 216.10M | 139.50M | 177.60M | 25.90M | 159.40M | 99.50M |
| Operating Cash Flow | 226.70M | 167.90M | 196.30M | 77.30M | 184.40M | 121.40M |
| Investing Cash Flow | -20.40M | -25.50M | -15.30M | -50.60M | -25.00M | -21.90M |
| Financing Cash Flow | -152.90M | -185.90M | -134.20M | -99.50M | -47.00M | -44.00M |
Dr. Martens Plc Technical Analysis
Dr. Martens Plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | £7.75B | 26.30 | 0.68% | 0.94% | 14.13% | -96.12% | |
67 Neutral | £839.26M | 184.79 | 1.23% | 2.94% | -10.20% | -93.32% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
60 Neutral | £1.39B | 13.21 | 5.01% | 1.15% | 2.71% | -34.19% | |
55 Neutral | £700.25M | -4.54 | -18.75% | ― | -20.36% | 44.33% | |
46 Neutral | £274.50M | -0.93 | -62.59% | ― | -15.86% | -18.46% | |
38 Underperform | £154.49M | -0.46 | -185.68% | ― | -45.91% | -120.22% |
Dr. Martens Plc Corporate Events
Dr. Martens plc announced a transaction involving its Chief Executive Officer, Ije Nwokorie, who sold shares to cover tax and national insurance liabilities following the vesting of restricted stock units. This transaction is part of a buyout arrangement to secure Nwokorie’s recruitment, reflecting the company’s adherence to its remuneration policy and potentially impacting its executive compensation strategy.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £90.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens Plc has announced transactions involving its directors under the company’s Share Incentive Plan (SIP). On October 13, 2025, CEO Ije Nwokorie and CFO Giles Wilson acquired Partnership Shares and were granted Matching Shares, reflecting the company’s commitment to employee investment and engagement. This move underlines Dr. Martens’ strategic focus on aligning management interests with shareholder value, potentially enhancing its market position and stakeholder confidence.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £90.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens Plc announced transactions involving the acquisition of ordinary shares by key executives under its Share Incentive Plan (SIP). The plan allows employees to purchase shares and receive matching shares, promoting employee ownership and aligning interests with company performance. This move reflects the company’s commitment to involving its leadership in its financial growth, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £90.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens Plc announced that its total issued ordinary share capital consists of 966,407,209 shares, each carrying one voting right. This information is crucial for shareholders to determine their notification requirements under the FCA’s rules, impacting how they manage their interests in the company.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £86.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens has announced a new distribution partnership with Beside Group in the UAE, marking its entry into the UAE market, and with Crosby in Latin America, expanding its presence in the region with new stores in Santiago, Chile, and Buenos Aires, Argentina. These partnerships align with Dr. Martens’ strategy to enter new growth markets with a capital-light approach, aiming to increase its consumer reach and strengthen its market position in these regions.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £86.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens Plc announced that its directors and persons discharging managerial responsibility acquired shares under the company’s Share Incentive Plan (SIP). The SIP allows employees to purchase shares and receive matching shares, enhancing employee engagement and aligning interests with shareholders. This move reflects the company’s commitment to employee participation in its growth and may positively impact its market positioning by fostering a sense of ownership among its workforce.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £86.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens plc announced recent share transactions involving Giles Wilson, the Chief Financial Officer, and Katie Wilson, a person closely associated with him. On September 1, 2025, Giles Wilson purchased 105,838 shares and sold 105,785 shares, while Katie Wilson purchased 30,019 shares and sold 30,000 shares. These transactions, conducted on the London Stock Exchange, reflect strategic movements into ISAs, indicating a potential focus on tax-efficient investment strategies. The transactions are significant for stakeholders as they highlight the financial maneuvers of key company figures, potentially impacting market perceptions and investor confidence.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £86.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens Plc announced that its issued ordinary share capital consists of 966,401,835 shares, each with one voting right, and no shares are held in Treasury. This figure is crucial for shareholders to determine their notification requirements under the FCA’s rules, impacting their stake disclosures and transparency obligations.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £86.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens Plc announced that its directors and persons discharging managerial responsibility (PDMRs) have participated in the company’s Share Incentive Plan (SIP). Under this plan, employees can purchase shares from their monthly salary and receive matching shares from the company at no additional cost. On August 11, 2025, CEO Ije Nwokorie and CFO Giles Wilson acquired 194 partnership shares each at 77.45 pence per share and were awarded an equal number of matching shares. This initiative reflects the company’s commitment to employee engagement and aligns the interests of management with shareholders, potentially strengthening the company’s market position.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £0.85 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens Plc has announced that its total issued ordinary share capital consists of 966,370,412 shares, each with one voting right, and none held in treasury. This information is crucial for shareholders to determine their notification requirements under FCA rules, impacting their stake management and transparency obligations.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £80.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens Plc has announced transactions involving the purchase of ordinary shares by its CEO and CFO under the Global Bonus Scheme. These transactions are part of the company’s remuneration policy, which requires executive directors to invest a portion of their annual bonuses into company shares, holding them for a minimum of two years. This move is likely to align the interests of the executives with those of the shareholders, potentially impacting the company’s market perception positively.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £0.85 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.